Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07502443 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

Study acronym: Brilliance NT2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 38 → 44 locations Eligibility criteria expanded, about 6 words · Secondary endpoints: details revised at 2 of 7 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 2 of 7 entries
  2. Trial sites expanded: 28 → 38 locationsv8
  3. Trial sites expanded: 19 → 28 locationsv7
  4. Trial sites expanded: 15 → 19 locationsv6
  5. Trial sites expanded: 8 → 15 locationsv5
  6. Start date changed from estimate of Apr 2026 to Apr 22, 2026v4
  7. Trial sites expanded: 2 → 8 locationsv3
  8. Recruitment opened Study sites: 0 to 2v2 Show 1 more changeShow less
    • Study sites: 0 to 2
  9. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Alkermes
10 trials monitored
See 1 trial at risk
The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.
Trial Details
NCT Number NCT07502443
Lead Sponsor Alkermes, Inc.
Conditions Narcolepsy Type 2
Enrollment 176 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov